top of page


AstraZeneca acquires Omniose to expand bacterial conjugate vaccine technology
AstraZeneca has completed its acquisition of US vaccine technology company Omniose, adding a proprietary bacterial bioconjugation platform to strengthen development of vaccines against serious infections and antimicrobial-resistant pathogens.

nuaxia
6 days ago2 min read


European Commission approves Enhertu for residual HER2-positive early breast cancer after neoadjuvant therapy
The European Commission has approved Enhertu for patients with residual HER2-positive early breast cancer, extending the antibody-drug conjugate into a curative-intent treatment setting.

nuaxia
Nov 22 min read


FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults
The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria.

nuaxia
Oct 222 min read


AstraZeneca signs $1.5 billion AI drug discovery collaboration with insitro for cardiometabolic diseases
AstraZeneca and insitro have entered a $1.5 billion AI-enabled drug discovery collaboration targeting difficult-to-treat cardiometabolic diseases.

nuaxia
Oct 162 min read


AstraZeneca invests $2bn in Summit Therapeutics and expands ivonescimab cancer collaboration
AstraZeneca is investing $2bn in Summit Therapeutics alongside a clinical collaboration focused on combinations involving the PD-1/VEGF bispecific antibody ivonescimab.

nuaxia
Sep 302 min read


FDA grants accelerated approval to Etcamah combination for ESR1-mutated advanced breast cancer
The FDA has granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

nuaxia
Sep 82 min read


European Commission approves Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

nuaxia
Sep 22 min read


AstraZeneca Acquires Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal
The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.

nuaxia
Jul 153 min read


AstraZeneca Licences Sino Biopharmaceutical’s TQC3721 Respiratory Drug in Potential $1.9bn Deal
The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China.

nuaxia
Jul 103 min read


AstraZeneca and Ionis Miss Primary Endpoint in Phase III ATTR-CM Trial for Eplontersen
The setback clouds expansion plans for the RNA-targeted therapy after a pivotal cardiovascular outcomes study failed to demonstrate a significant benefit in patients with transthyretin amyloid cardiomyopathy.

nuaxia
Jul 103 min read


AstraZeneca Expands China Partnerships with Up to $2.1bn Respiratory Drug Deal
The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.

nuaxia
Jul 93 min read


FDA Approves AstraZeneca’s Imfinzi Plus BCG for High-Risk Bladder Cancer
The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care.

nuaxia
Jun 22 min read
bottom of page